Exavir (Series A)

Funding Details
Awarder
Gaingels
Date Award
May 24, 2024
Vertical
Healthcare and Biotech
Funding URL
View Funding Page
Valuation
$11,000,000

Company Info
Founders
Alborz Yazdi
Company Description
Developing best-in-class ultra-long-acting medicines for chronic viral infections and CNS disorders, where better adherence and compliance can dramatically improve patient outcomes. Exavir Therapeutics is a preclinical stage biotechnology company dedicated to eliminating HIV and other viral infections.
Market
Healthcare & Wellness

Links
Back to Home Back to Healthcare and Biotech Deals View Funding Announcement